Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.

Pharmacogenetics and genomics - 1 Dec 2014

Abubakar Murtala B, Wei Keat, Gan Siew Hua

Abstract excerpt

Breast cancer is a common cause of cancer mortality among women. Several genetic factors have been implicated in its development. Current treatment guidelines for estrogen receptor-positive breast cancer recommend that anastrozole [or any of the other two aromatase inhibitors (letrozole and exemestane)] is used as an alternative to tamoxifen or following several years of tamoxifen treatment. Nevertheless, this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Aromatase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Glucuronosyltransferase

Share to Nitriles

Share to Postmenopause

Share to Precision Medicine

Share to Triazoles

Source

Identifiers

PMID: 25203739
DOI: 10.1097/FPC.0000000000000092

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.PMID 25203739Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Semantic proximity Read ↗

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of TamoxifenSemantic proximity Read ↗

Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.Semantic proximity Read ↗

Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients' Population.Semantic proximity Read ↗

Association Analysis among Tamoxifen Metabolites and Genetic Polymorphisms in Hormone-Dependent Chilean Breast Cancer Patients: A Preliminary StudySemantic proximity Read ↗

Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.Semantic proximity Read ↗

Anastrozole.Semantic proximity Read ↗

Significance of the Estrogen Hormone and Single Nucleotide Polymorphisms in the Progression of Breast Cancer among Female.Semantic proximity Read ↗

Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis.Semantic proximity Read ↗

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Semantic proximity Read ↗

A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.